Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
914actual
Sites
124
Countries
Australia, Belgium, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-09-05 | actual | When the study began enrolling |
| Primary completion | 2023-02-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2017-05-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Non-Small Cell Lung Cancer
- Castration-resistant Prostate Cancer
- Triple Negative Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Hepatocellular Carcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Colorectal Cancer
- Head and Neck Cancer
- Differentiated Thyroid Cancer
- Lower Esophageal Cancer
Interventions
- Drug: cabozantinib — also filed as Cabometyx, XL184
- Drug: atezolizumab — also filed as Tecentriq
- Drug: cabozantinib — also filed as Cabometyx, XL184
- Drug: cabozantinib — also filed as Cabometyx, XL184
Primary outcomes
what the primary-completion date above is the date OFDose Escalation: MTD/Recommended Dose
measured Up to Day 21
Dose Expansion: ORR
measured Up to a maximum of 59 months
Publications
- PMID 39965176 — linked by the registry
- PMID 38204489 — linked by the registry
- PMID 35690072 — linked by the registry
- PMID 34491815 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed